NCT03726866View on ClinicalTrials.gov

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

January 15, 2019

Study Completion Date

January 15, 2019

Conditions
DyslipidemiasHypertension
Interventions
DRUG

Sequence 1

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 2

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 3

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 4

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 5

D326, D337 or CKD-828 for 9 days

DRUG

Sequence 6

D326, D337 or CKD-828 for 9 days

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, University of Ulsan, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT03726866 - A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects | Biotech Hunter | Biotech Hunter